From The Stage

The Evolution of Bioanalytical Outsourcing Partnerships

Jim Datin
Posted by Jim Datin / / CRO Selection, Industry Update

Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. To fully understand how we have arrived, as an industry, at a place where outsourcing is vital to our collective success, it is helpful to look back at where we started.

Biologics Market Growth Demands Quality Science that Can Keep Pace

Jim Datin
Posted by Jim Datin / / CRO Selection, Industry Update

It is anticipated that biologics will comprise 50% of the top 100 drugs by 2021. But, given the structural complexities of large molecule drugs, adherence to stringent quality standards will be a necessary part of effectively bringing these innovations to market. We discuss why it will be essential for pharma and biotech companies to align with outsourced partners that can deliver the quality science large molecule bioanalysis demands.